The present invention provides nutritional supplements comprising alginate, in combination with pectin, which will form hydrogels in the stomach when exposed to the low pH of the gastric juice. The formation of a hydrogel will lead to delayed release of sugars and other active ingredients in the stomach. The nutritional supplements can comprise high concentrations of sugars and complex carbohydrates without causing unwanted gastrointestinal symptoms.

The present invention provides nutritional supplements comprising alginate, preferably in combination with pectin, which will form hydrogels in the stomach when exposed to the low pH of the gastric juice. The formation of a hydrogel will lead to delayed release of sugars and other active ingredients in the stomach. The nutritional supplements can comprise high concentrations of sugars and complex carbohydrates without causing unwanted gastrointestinal symptoms.

A nutritional supplement provides Vitamin E; sophora flavescens extract; zinc; and at least two ingredients selected from the group consisting of hemp grapeseed extract, hemp curcumin, hemp boswellia, hemp black pepper, hemp magnolia, hemp ginger, hemp oregano leaf, hemp orange peel, hemp methyl sulfano methane (MSM), hemp poplar, hemp chia, hemp meadow sweet, hemp clove powder, hemp cinnamon, and hemp basil (excluding hay basil and hay basil extract). The supplement can be used to reduce joint inflammation, reduce stiffness, reduce lameness, improve flexion, and improve amount of movement and mobility by supporting joint health.

A nutritional supplement provides Vitamin E; sophora flavescens extract; zinc; and at least two ingredients selected from the group consisting of hemp grapeseed extract, hemp curcumin, hemp boswellia, hemp black pepper, hemp magnolia, hemp ginger, hemp oregano leaf, hemp orange peel, hemp methyl sulfano methane (MSM), hemp poplar, hemp chia, hemp meadow sweet, hemp clove powder, hemp cinnamon, and hemp basil (excluding hay basil and hay basil extract). The supplement can be used to reduce joint inflammation, reduce stiffness, reduce lameness, improve flexion, and improve amount of movement and mobility by supporting joint health.

Choline alfoscerate is a drug used to improve cerebrovascular diseases and brain metabolism. It is a drug with proven safety, which has no effect on the kidney and liver and with no severe side effect reported. When administered to a patient with muscle cramps, it can significantly reduce pain and the occurrence of muscle cramps. Accordingly, it may be used as an active ingredient in a pharmaceutical composition for treating or preventing muscle cramps and a health functional food composition for improving muscle cramps and may also be used for a method for treating muscle cramps by administering choline alfoscerate. In addition, choline alfoscerate may also be used to prepare a medication for treating muscle cramps.

Choline alfoscerate is a drug used to improve cerebrovascular diseases and brain metabolism. It is a drug with proven safety, which has no effect on the kidney and liver and with no severe side effect reported. When administered to a patient with muscle cramps, it can significantly reduce pain and the occurrence of muscle cramps. Accordingly, it may be used as an active ingredient in a pharmaceutical composition for treating or preventing muscle cramps and a health functional food composition for improving muscle cramps and may also be used for a method for treating muscle cramps by administering choline alfoscerate. In addition, choline alfoscerate may also be used to prepare a medication for treating muscle cramps.

A synthetic nutritional composition comprising a mineral for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

A synthetic nutritional composition comprising a mineral for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.

The present disclosure relates to a method for preventing, alleviating, improving or treating female hormone regulation disorder or symptoms, which contains a green tea extract with contents of ingredients changed. Specifically, the method according to an aspect of the present disclosure includes a step of administering an effective amount of a green tea extract, which contains (−)-gallocatechin gallate (GCG) and (−)-epigallocatechin gallate (EGCG) at specific contents, to a subject in need thereof, and may exhibit an effect of preventing, alleviating, improving or treating female hormone regulation disorder or symptoms.

The present disclosure relates to a method for preventing, alleviating, improving or treating female hormone regulation disorder or symptoms, which contains a green tea extract with contents of ingredients changed. Specifically, the method according to an aspect of the present disclosure includes a step of administering an effective amount of a green tea extract, which contains (−)-gallocatechin gallate (GCG) and (−)-epigallocatechin gallate (EGCG) at specific contents, to a subject in need thereof, and may exhibit an effect of preventing, alleviating, improving or treating female hormone regulation disorder or symptoms.